85,929 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Tocqueville Asset Management L.P.

Key Points

• Tocqueville Asset Management L.P. has acquired a new stake in Regeneron Pharmaceuticals, purchasing 85,929 shares valued at approximately $54.5 million, making it the fund's 23rd largest holding.
• Regeneron reported impressive earnings with $12.89 EPS, surpassing analyst expectations by $4.46, along with quarterly revenue of $3.68 billion, a 3.6% increase year-over-year.
• The company declared a quarterly dividend of $0.88 per share, with an annualized yield of 0.6%, reflecting a payout ratio of 8.87%.

Tocqueville Asset Management L.P. acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 85,929 shares of the biopharmaceutical company's stock, valued at approximately $54,499,000. Regeneron Pharmaceuticals accounts for approximately 0.9% of Tocqueville Asset Management L.P.'s portfolio, making the stock its 23rd largest holding. Tocqueville Asset Management L.P. owned approximately 0.08% of Regeneron Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Capital International Investors raised its stake in Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after purchasing an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after buying an additional 810,144 shares in the last quarter. Nuveen LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $343,764,000. Finally, Pacer Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 2,296.9% during the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after purchasing an additional 390,374 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $2.13 during mid-day trading on Tuesday, hitting $571.78. The company's stock had a trading volume of 854,560 shares, compared to its average volume of 979,587. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The stock's 50-day moving average is $545.33 and its two-hundred day moving average is $593.59. The firm has a market capitalization of $60.60 billion, a PE ratio of 14.80, a price-to-earnings-growth ratio of 1.91 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3,675,600 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period last year, the business earned $11.56 earnings per share. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on REGN. The Goldman Sachs Group cut their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a report on Friday, August 1st. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday, August 4th. Rothschild & Co Redburn initiated coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price target on the stock. Finally, Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $829.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.